BioSpace News Archive

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) today announced additional details regarding the planned design of its SERENITY At-Home Phase 3 trial*to evaluate BXCL501, the Company’s investigational, proprietary, orally dissolving film formulation of dexmedetomidine, as a potential acute treatment for agitation associated with bipolar disorders or schizophrenia in the home setting.

Plus Therapeutics, Inc. today announced it has been selected for funding by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP).

XORTX Therapeutics Inc. is pleased to announce a research paper titled “Raising serum uric acid with a uricase inhibitor worsens PKD in rat and mouse models” has been accepted for publication in the peer-reviewed American Journal.

Kraig Biocraft Laboratories, Inc., announces what it considers to be a major milestone. The Company has completed rearing of the first generation of its new BAM-1 parental strains as part of its spring production trial.

ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumour cell solutions for use in research, drug development and clinical oncology, is pleased to announce that the European Patent Office has granted a European Patent for its innovative CellKeep™ slide.

Nicox SA, an international ophthalmology company, provided the revenue and cash position for Nicox SA and its subsidiaries for the first quarter of 2024 and financial results for Nicox SA for the full year of 2023, as approved by the Board of Directors on April 19, 2024, and provided an update on key future milestones.

Kynos Therapeutics Ltd announces the key findings from the first-in-human Phase I trial of its lead drug candidate, KNS366.

Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., and Sumitomo Mitsui Banking Corporation announced that the three companies signed a master agreement on April 22, 2024, to establish a joint venture company.

KalVista Pharmaceuticals, Inc. announced that William C. Fairey has been appointed to the Company’s Board of Directors, effective immediately.

BioNTech SE will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.